Fucoidan Modulates Gut–Liver Axis to Mitigate Chemotherapy Hepatotoxicity

Study Background and Research Question

Chemotherapy-induced hepatotoxicity, particularly steatohepatitis, is a significant complication that impairs patient outcomes and limits treatment regimens. Irinotecan (CPT-11), a widely used topoisomerase I inhibitor, is effective against advanced solid tumors but is commonly associated with severe hepatic side effects, including non-alcoholic steatohepatitis (NASH). The underlying mechanisms linking irinotecan to liver injury remain incompletely defined, with emerging attention to the gut–liver axis and the role of inflammatory mediators in driving hepatic inflammation. This context frames a critical research question: Can targeting the gut–liver axis with bioactive polysaccharides such as fucoidan mitigate irinotecan-induced steatohepatitis?

Key Innovation from the Reference Study

The recent study by Cai et al. (2026) provides mechanistic insight into the gut–liver interplay during chemotherapy-induced liver injury. The innovation lies in demonstrating that fucoidan—a complex, fucose-rich sulfated α-L-fucan derived from brown seaweed—protects against irinotecan-induced steatohepatitis by restoring intestinal barrier function, modulating gut microbiota, and suppressing hepatic neutrophil extracellular trap (NET) formation. This work shifts the paradigm from direct hepatic interventions to systemic, barrier-focused strategies that address upstream contributors to chemotherapy toxicity.

Methods and Experimental Design Insights

The authors utilized a murine model to replicate clinical patterns of irinotecan-induced steatohepatitis. Key aspects of the experimental design included:

• Induction of steatohepatitis via repeated CPT-11 administration.
• Assessment of gut barrier integrity using in vivo imaging and quantification of tight junction proteins.
• Analysis of hepatic inflammation and NET formation through immunohistochemistry and detection of PAD4, a NET biomarker.
• Evaluation of gut microbiota composition pre- and post-fucoidan administration using 16S rRNA sequencing.
• Use of antibiotic-mediated microbiota depletion to assess the irreplaceable role of gut flora in mediating fucoidan’s protective effects.

This multifaceted approach enabled the authors to trace the trajectory from barrier dysfunction to hepatic inflammation and to dissect the contribution of microbial and immunological components.

Core Findings and Why They Matter

The study showed that CPT-11 disrupts the intestinal barrier, allowing translocation of bacterial lipopolysaccharide (LPS) into the portal circulation. This LPS influx triggers hepatic NET formation, amplifying inflammation and driving steatohepatitis. Fucoidan administration exerted multiple protective effects:

• Preservation of Intestinal Barrier: Fucoidan restored the expression of tight junction proteins (e.g., claudin and occludin), reducing paracellular permeability.
• Gut Microbiota Modulation: Partial normalization of microbial composition was observed, suggesting an immune-modulating agent role for fucoidan.
• Suppression of NETs: Hepatic accumulation of NETs (as indicated by PAD4 expression) was markedly reduced, mitigating downstream inflammatory cascades.
• Dependency on Microbiota: Antibiotic-induced microbiota depletion exacerbated liver injury and abrogated the benefits of fucoidan, underlining the synergistic relationship between the polysaccharide and the resident gut flora.

Together, these data support a model in which fucoidan acts as a barrier-protective and anti-inflammatory sulfated polysaccharide, preventing chemotherapy-associated liver injury by intervening at the gut–liver interface. This approach is particularly meaningful because it addresses an upstream driver of hepatic damage, rather than attempting to treat inflammation after it has occurred.

Comparison with Existing Internal Articles

Several recent reviews and scenario-driven analyses reinforce and extend the mechanistic findings reported here. For example, "Fucoidan in Oncology: Gut–Liver Axis and Chemotherapy Protection" previously highlighted the dual functionality of sulfated α-L-fucan in both anticancer therapy and gut–liver axis modulation, aligning with the present study’s emphasis on barrier integrity and inflammation control. Furthermore, "Fucoidan: Mechanistic Powerhouse and Translational Catalyst" explored the translational significance of fucoidan in oncology and immunology, including apoptosis induction in prostate cancer cells and immune activation, which complements the current focus on its immune-modulating properties in the context of hepatic injury.

While much attention has centered on fucoidan’s role as an anticancer polysaccharide, this new research emphasizes a protective dimension that is equally crucial for sustaining therapy regimens and minimizing off-target toxicity. The mechanistic specificity—spanning from apoptosis induction in cancer cells to maintenance of gut–liver homeostasis—underscores fucoidan’s versatility and supports its continued evaluation in both cancer and supportive care research domains.

Limitations and Transferability

Several limitations merit consideration. First, while the murine model of irinotecan-induced steatohepatitis is clinically relevant, species-specific differences in gut microbiota and immune responses may affect the direct translation to human patients. The molecular details of how fucoidan interacts with host and microbial factors remain partially unresolved, especially regarding the fine structure–activity relationship of sulfated polysaccharides from brown seaweed. Additionally, the beneficial effects of fucoidan were shown to be dependent on an intact microbiome; in patients with altered or depleted microbiota (e.g., due to broad-spectrum antibiotics), efficacy may be diminished.

Nevertheless, the underlying principle—that restoration of barrier function and suppression of NET-driven inflammation can mitigate chemotherapy toxicity—is likely to apply to other forms of chemotherapy-induced hepatotoxicity beyond irinotecan, given the shared features of gut–liver axis disruption and sterile inflammation in these settings.

Protocol Parameters

• Fucoidan administration: In murine models, fucoidan was administered concurrently with or prior to CPT-11 to maximize barrier protection and anti-inflammatory effects. Researchers should adjust dosing and timing based on their specific experimental designs and the characteristics of their model systems.
• Antibiotic pretreatment (if used): When modeling microbiota depletion, initiate broad-spectrum antibiotics at least 3–5 days prior to chemotherapy and continue throughout the study period to ensure sustained suppression of gut flora.
• Barrier function assessment: Employ in vivo imaging and quantification of tight junction protein expression to monitor the impact of interventions on intestinal integrity.
• NETs detection: Use immunohistochemistry for PAD4 and related markers to quantify hepatic NET formation as a readout for inflammatory activation.

Why this cross-domain matters, maturity, and limitations

The cross-domain relevance of fucoidan’s dual actions—as both an anticancer polysaccharide and a gut–liver axis modulator—reflects an emerging recognition that supportive interventions can sustain the viability of primary cancer therapies. By targeting the interface between microbial, immune, and hepatic systems, this strategy offers a more holistic approach to oncology care. However, clinical translation requires further validation in human subjects and careful stratification according to individual microbiome status and chemotherapeutic regimens.

Research Support Resources

For researchers seeking to replicate or extend these findings, Fucoidan (SKU C4038, APExBIO) is a highly purified sulfated α-L-fucan suitable for mechanistic and preclinical studies. Its defined purity and solubility profile facilitate reproducibility in both in vitro and in vivo workflows. Used appropriately, this reagent can support investigations ranging from apoptosis induction in prostate cancer cells to modulation of immune responses and barrier function in models of chemotherapy-induced tissue injury, as described in the reference study.